Us Renal Care Falls Church Dialysis is a medicare approved dialysis facility center in Falls Church, Virginia and it has 13 dialysis stations. It is located in Fairfax county at 6541 Arlington Blvd, Falls Church, VA, 22042. You can reach out to the office of Us Renal Care Falls Church Dialysis at (703) 533-8247. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. Us Renal Care Falls Church Dialysis has the following ownership type - Profit. It was first certified by medicare in January, 2017. The medicare id for this facility is 492705 and it accepts patients under medicare ESRD program.
| Name | Us Renal Care Falls Church Dialysis |
|---|---|
| Location | 6541 Arlington Blvd, Falls Church, Virginia |
| No. of Dialysis Stations | 13 |
| Medicare ID | 492705 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 6541 Arlington Blvd, Falls Church, Virginia, 22042 | |
| (703) 533-8247 | |
| Not Available |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
| NPI Number | 1215485552 |
| Organization Name | U.s. Renal Care, Inc. |
| Doing Business As | Usrc Falls Church Llc |
| Address | 6541 Arlington Blvd Falls Church, Virginia, 22042 |
| Phone Number | (703) 533-8247 |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 10 |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 25 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 119 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 2 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 5 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Us Renal Care Falls Church Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 28 |
| Hypercalcemia patient months | 128 |
| Patients with Serumphosphor | 35 |
| Patients with Serumphosphor less than 3.5 mg/dL | 16 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 5 |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 23 |
| Patient months included in arterial venous fistula and catheter summaries | 111 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 65 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 20 |
News Archive
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.
New research led by the Hip Implant Prosthesis Study team at the University of Bristol Medical School has shown that small-head cemented metal-on-plastic hip replacements are the most cost-effective in men and women older than 65 years.
Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.
Clinicians should consider how the way we think can make us vulnerable to obesity, and how obesity is genetically intertwined with brain structure and mental performance, according to new research.
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
› Verified 4 days ago